HIV-1 and the immune response to TB

Future Virology

Volumn 8, Issue 1, 2013, Pages 57-80

  Walker, Naomi F ^a,b   Meintjes, Graeme ^a,b   Wilkinson, Robert J ^a,b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

antiretroviral therapy; ART; diagnosis; HIV; immunity; immunopathology; TB; TB associated immune reconstitution inflammatory syndrome; TB IRIS; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CIGARETTE SMOKE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL KILLER CELL RECEPTOR; NEUTROPHIL COLLAGENASE; PREDNISONE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; BODY BURDEN; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC TEST; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSPOT ASSAY; EPIDEMIOLOGICAL DATA; GRANULOMA; GROUPS BY AGE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION RISK; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; LUNG TUBERCULOSIS; MACROPHAGE FUNCTION; MALNUTRITION; MEMORY T LYMPHOCYTE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEUTROPHIL; PHAGOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SILICOSIS; TUBERCULOSIS; TUBERCULOUS PLEURISY; VIRUS REPLICATION; VITAMIN D DEFICIENCY; WORK ENVIRONMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84871599953     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.123     Document Type: Review

References (230)

1. WHO. Global Tuberculosis Control. WHO Press, Switzerland (2011).
2. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD. HIV infection and tuberculosis in South Africa: An urgent need to escalate the public health response. Lancet 374(9693), 921-933 (2009).
3. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: Comparison with rates in the community. PLoS One 7(3), e34156 (2012).
4. Chaisson RE, Martinson NA. Tuberculosis in Africa Y combating an HIV-driven crisis. N. Engl. J. Med. 358(11), 1089-1092 (2008).
5. Baeke F, Gysemans C, Korf H, Mathieu C. Vitamin D insufficiency: Implications for the immune system. Pediatr. Nephrol. 25(9), 1597-1606 (2010).
6. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: Convergence of two epidemics. Lancet Infect. Dis. 9(12), 737-746 (2009).
7. Burki T. Tackling tuberculosis in London's homeless population. Lancet 376(9758), 2055-2056 (2010).
8. Dunne FJ. Alcohol and the immune system. BMJ 298(6673), 543-544 (1989).
9. Chandra RK. Nutrition and the immune system from birth to old age. Eur. J. Clin. Nutr. 56(Suppl. 3), S73-S76 (2002).
10. Deveale B, Brummel T, Seroude L Immunity and aging: The enemy within? Aging Cell 3(4), 195-208 (2004).
11. Atun R, Raviglione M, Marais B, Zumla A. Tuberculosis control is crucial to achieve the MDGs. Lancet 376(9745), 940-941 (2010).
12. Martineau AR, Nhamoyebonde S, Oni T et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc. Natl Acad. Sci. USA 108(47), 19013-19017 (2011).
13. Geldmacher C, Zumla A, Hoelscher M. Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr. Opin. HIV AIDS 7(3), 268-275 (2012).
14. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191(2), 150-158 (2005).
15. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: A cohort study in South African mineworkers. Lancet 358(9294), 1687-1693 (2001).
16. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23(13), 1717-1725 (2009).
17. Kizza HM, Rodriguez B, Quinones-Mateu M et al. Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin. Diagn. Lab. Immunol. 12(11), 1298-1304 (2005).
18. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am. J. Respir. Crit. Care Med. 151(1), 129-135 (1995).
19. Whalen CC, Nsubuga P, Okwera A et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: A prospective epidemiologic study in Uganda. AIDS 14(9), 1219-1228 (2000).
20. Badri M, Ehrlich R, Wood R, Pulerwitz T, Maartens G. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area. Int. J. Tuberc. Lung Dis. 5(3), 225-232 (2001).
21. WHO. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO Press, Switzerland (2009).
22. Barry CE, 3rd, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7(12), 845-855 (2009).
23. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol. 17(5), 183-188 (2009).
24. Lawn SD, Kerkhoff AD, Wood R. Progression of subclinical culture-positive tuberculosis to symptomatic disease in HIV-infected individuals. AIDS 25(17), 2190-2191 (2011).
25. Oni T, Burke R, Tsekela R et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: Implications for TB screening. Thorax 66(8), 669-673 (2011).
26. Rangaka MX, Gideon HP, Wilkinson KA et al. Interferon release does not add discriminatory value to smear-negative HIVYtuberculosis algorithms. Eur. Respir. J. 39(1), 163-171 (2012).
27. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin. Chest Med. 30(4), 797-810, x (2009).
28. Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int. J. Tuberc. Lung Dis. 13(1), 39-46 (2009).
29. Pienaar E, Fluitt AM, Whitney SE, Freifeld AG, Viljoen HJ. A model of tuberculosis transmission and intervention strategies in an urban residential area. Comput. Biol. Chem. 34(2), 86-96 (2010).
30. Caley M, Fowler T, Welch S, Wood A. Risk of developing tuberculosis from a school contact: Retrospective cohort study, United Kingdom, 2009. Euro Surveill. 15(11), 19510 (2010).
31. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178(6), 2249-2254 (1993).
32. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178(6), 2243-2247 (1993).
33. Ottenhoff TH, Kumararatne D, Casanova JL. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. Immunol. Today 19(11), 491-494 (1998).
34. Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2(6), 561-572 (1995).
35. Newport MJ, Huxley CM, Huston S et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335(26), 1941-1949 (1996).
36. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345(15), 1098-1104 (2001).
37. Jouanguy E, Lamhamedi-Cherradi S, Lammas D et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. Genet. 21(4), 370-378 (1999).
38. Cooper AM. Cell-mediated immune responses in tuberculosis. Ann. Rev. Immunol. 27, 393-422 (2009).
39. Doenhoff MJ. Granulomatous inflammation and the transmission of infection: Schistosomiasis Y and TB too? Immunol. Today 19(10), 462-467 (1998).
40. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327(5964), 466-469 (2010).
41. Paige C, Bishai WR. Penitentiary or penthouse condo: The tuberculous granuloma from the microbe's point of view. Cell. Microbiol. 12(3), 301-309 (2010).
42. Doenhoff MJ. A role for granulomatous inflammation in the transmission of infectious disease: Schistosomiasis and tuberculosis. Parasitology 115(Suppl.), S113-S125 (1997).
43. Lucas S, Nelson AM. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Tuberculosis Pathogenesis, Protection and Control. Bloom BR (Ed.). American Society for Microbiology, Washington, DC, USA, 503-513 (1994).
44. Lucas SB, Hounnou A, Peacock C et al. The mortality and pathology of HIV infection in a west African city. AIDS 7(12), 1569-1579 (1993).
45. De Noronha AL, Bafica A, Nogueira L, Barral A, Barral-Netto M. Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production. Pathol. Res. Pract. 204(3), 155-161 (2008).
46. Shen JY, Barnes PF, Rea TH, Meyer PR. Immunohistology of tuberculous adenitis in symptomatic HIV infection. Clin. Exp. Immunol. 72(2), 186-189 (1988).
47. Nambuya A, Sewankambo N, Mugerwa J, Goodgame R, Lucas S. Tuberculous lymphadenitis associated with human immunodeficiency virus (HIV) in Uganda. J. Clin. Pathol. 41(1), 93-96 (1988).
48. Diedrich CR, Flynn JL. HIV-1/ Mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis? Infect. Immun. 79(4), 1407-1417 (2011).
49. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Ann. Rev. Pathol. 7, 353-384 (2012).
50. Toossi Z, Wu M, Rojas R et al. Induction of serine protease inhibitor 9 by Mycobacterium tuberculosis inhibits apoptosis and promotes survival of infected macrophages. J. Infect. Dis. 205(1), 144-151 (2012).
51. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263(5147), 678-681 (1994).
52. Pathak S, Wentzel-Larsen T, Asjo B. Effects of in vitro HIV-1 infection on mycobacterial growth in peripheral blood monocyte-derived macrophages. Infect. Immun. 78(9), 4022-4032 (2010).
53. Imperiali FG, Zaninoni A, La Maestra L, Tarsia P, Blasi F, Barcellini W. Increased Mycobacterium tuberculosis growth in HIV-1- infected human macrophages: Role of tumour necrosis factor-alpha. Clin. Exp. Immunol. 123(3), 435-442 (2001).
54. Meylan PR, Munis JR, Richman DD, Kornbluth RS. Concurrent human immunodeficiency virus and mycobacterial infection of macrophages in vitro does not reveal any reciprocal effect. J. Infect. Dis. 165(1), 80-86 (1992).
55. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog. 8(5), e1002689 (2012).
56. Mwandumba HC, Russell DG, Nyirenda MH et al. Mycobacterium tuberculosis resides in nonacidified vacuoles in endocytically competent alveolar macrophages from patients with tuberculosis and HIV infection. J. Immunol. 172(7), 4592-4598 (2004).
57. Patel NR, Swan K, Li X, Tachado SD, Koziel H. Impaired M. tuberculosis-mediated apoptosis in alveolar macrophages from HIV+ persons: Potential role of IL-10 and BCL-3. J. Leukoc. Biol. 86(1), 53-60 (2009).
58. Kumawat K, Pathak SK, Spetz AL, Kundu M, Basu J. Exogenous Nef is an inhibitor of Mycobacterium tuberculosis-induced tumor necrosis factor-alpha production and macrophage apoptosis. J. Biol. Chem. 285(17), 12629-12637 (2010).
59. Killian MS. Dual role of autophagy in HIV-1 replication and pathogenesis. AIDS Res. Ther. 9(1), 16 (2012).
60. Van Grol J, Subauste C, Andrade RM, Fujinaga K, Nelson J, Subauste CS. HIV-1 inhibits autophagy in bystander macrophage/ monocytic cells through SrcYAkt and STAT3. PLoS One 5(7), e11733 (2010).
61. Borel S, Espert L, Biard-Piechaczyk M. Macroautophagy regulation during HIV-1 infection of CD4+ T cells and macrophages. Front. Immunol. 3, 97 (2012).
62. Mehta S, Giovannucci E, Mugusi FM et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 5(1), e8770 (2010).
63. Wilkinson RJ, Llewelyn M, Toossi Z et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: A caseYcontrol study. Lancet 355(9204), 618-621 (2000).
64. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: A systematic review and meta-analysis. Int. J. Epidemiol. 37(1), 113-119 (2008).
65. Mehta S, Hunter DJ, Mugusi FM et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J. Infect. Dis. 200(7), 1022-1030 (2009).
66. Hoshino Y, Hoshino S, Gold JA et al. Mechanisms of polymorphonuclear neutrophil-mediated induction of HIV-1 replication in macrophages during pulmonary tuberculosis. J. Infect. Dis. 195(9), 1303-1310 (2007).
67. Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR Neutrophils in tuberculosis: Friend or foe? Trends Immunol. 33(1), 14-25 (2012).
68. Eum SY, Kong JH, Hong MS et al Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137(1), 122-128 (2010).
69. Martineau AR, Newton SM, Wilkinson KA et al. Neutrophil-mediated innate immune resistance to mycobacteria. J. Clin. Invest. 117(7), 1988-1994 (2007).
70. Berry MPR, Graham CM, Mcnab FW et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466(7309), 973-977 (2010).
71. Kwan CK, Ernst JD. HIV and tuberculosis: A deadly human syndemic. Clin. Microbiol. Rev. 24(2), 351-376 (2011).
72. Mogues T, Goodrich ME, Ryan L, Lacourse R, North RJ. The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J. Exp. Med. 193(3), 271-280 (2001).
73. Dartois V. Immunopathology of tuberculosis disease across species. In: A Colour Atlas of Comparative Pathology of Pulmonary Tuberculosis. Leong FJ, Dartois V, Dick T (Eds). Taylor and Francis Group, LLC, UK (2011).
74. Diedrich CR, Mattila JT, Klein E et al. Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 5(3), e9611 (2010).
75. Lin PL, Rutledge T, Green AM et al. CD4 T cell depletion exacerbates acute Mycobacterium tuberculosis while reactivation of latent infection is dependent on severity of tissue depletion in cynomolgus macaques. AIDS Res. Hum. Retroviruses doi:10.1089/ aid.2012.0028 (2012) (Epub ahead of print).
76. Lin PL, Pawar S, Myers A et al. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 74(7), 3790-3803 (2006).
77. Lin PL, Rodgers M, Smith L et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77(10), 4631-4642 (2009).
78. Mattila JT, Diedrich CR, Lin PL, Phuah J, Flynn JL. Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation. J. Immunol. 186(6), 3527-3537 (2011).
79. Law KF, Jagirdar J, Weiden MD, Bodkin M, Rom WN. Tuberculosis in HIV-positive patients: Cellular response and immune activation in the lung. Am. J. Respir. Crit. Care Med. 153(4 Pt 1), 1377-1384 (1996).
80. Barnes PF, Mistry SD, Cooper CL, Pirmez C, Rea TH, Modlin RL. Compartmentalization of a CD4+ T lymphocyte subpopulation in tuberculous pleuritis. J. Immunol. 142(4), 1114-1119 (1989).
81. Geldmacher C, Schuetz A, Ngwenyama N et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J. Infect. Dis. 198(11), 1590-1598 (2008).
82. Kalsdorf B, Scriba TJ, Wood K et al. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am. J. Respir. Crit. Care Med. 180(12), 1262-1270 (2009).
83. Mansoor N, Scriba TJ, De Kock M et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille CalmetteYGuerin vaccine. J. Infect. Dis. 199(7), 982-990 (2009).
84. Rangaka MX, Diwakar L, Seldon R et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin. Infect. Dis. 44(12), 1639-1646 (2007).
85. Matthews K, Ntsekhe M, Syed F et al. HIV-1 infection alters CD4+ memory T-cell phenotype at the site of disease in extrapulmonary tuberculosis. Eur. J. Immunol. 42(1), 147-157 (2012).
86. Wilkinson KA, Seldon R, Meintjes G et al. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am. J. Respir. Crit. Care Med. 180(7), 674-683 (2009).
87. Geldmacher C, Ngwenyama N, Schuetz A et al. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J. Exp. Med. 207(13), 2869-2881 (2010).
88. Geldmacher C, Koup RA. Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection. Trends Immunol. 33(5), 207-214 (2012).
89. Wilkinson KA, Wilkinson RJ. Polyfunctional T cells in human tuberculosis. Eur. J. Immunol. 40(8), 2139-2142 (2010).
90. Ronsholt FF, Ullum H, Katzenstein TL, Gerstoft J, Ostrowski SR. T cell subset distribution in HIV-1 infected patients after 12 years of treatment induced viraemic suppression. J. Acquir. Immune Defic. Syndr. 61(3), 270-278 (2012).
91. Chomont N, El-Far M, Ancuta P et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15(8), 893-900 (2009).
92. Scriba TJ, Tameris M, Smit E et al. A Phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am. J. Respir. Crit. Care Med. 185(7), 769-778 (2012).
93. Caccamo N, Guggino G, Joosten SA et al. Multifunctional CD4+ T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 40(8), 2211-2220 (2010).
94. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39(3), 723-729 (2009).
95. Day CL, Abrahams DA, Lerumo L et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. 187(5), 2222-2232 (2011).
96. Descours B, Avettand-Fenoel V, Blanc C et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin. Infect. Dis. 54(10), 1495-1503 (2012).
97. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300(5617), 339-342 (2003).
98. Komanduri KV, Donahoe SM, Moretto WJ et al. Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1- infected subjects. Virology 279(2), 459-470 (2001).
99. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 89(24), 12013-12017 (1992).
100. Van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30(12), 3689-3698 (2000).
101. Stenger S, Hanson DA, Teitelbaum R et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282(5386), 121-125 (1998).
102. Woodworth JS, Wu Y, Behar SM. Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo. J. Immunol. 181(12), 8595-8603 (2008).
103. Canaday DH, Wilkinson RJ, Li Q, Harding CV, Silver RF, Boom WH. CD4+ and CD8+ T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J. Immunol. 167(5), 2734-2742 (2001).
104. Bruns H, Meinken C, Schauenberg P et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J. Clin. Invest. 119(5), 1167-1177 (2009).
105. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50(2), 372-379 (2004).
106. Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: Another mechanism revealed. J. Clin. Invest. 119(5), 1079-1082 (2009).
107. Champagne P, Ogg GS, King AS et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410(6824), 106-111 (2001).
108. Hunt PW. HIV and inflammation: Mechanisms and consequences. Curr. HIV/ AIDS Rep. 9, 139-147 (2012).
109. Hogg AE, Bowick GC, Herzog NK, Cloyd MW, Endsley JJ. Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1. J. Leukoc. Biol. 86(5), 1191-1203 (2009).
110. Zheng CF, Ma LL, Jones GJ et al. Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood 109(5), 2049-2057 (2007).
111. Franks I. Viral hepatitis: Interleukin 21 has a key role in age-dependent response to HBV. Nat. Rev. Gastroenterol. Hepatol. 8(5), 243 (2011).
112. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324(5934), 1572-1576 (2009).
113. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 324(5934), 1569-1572 (2009).
114. Iannello A, Tremblay C, Routy JP, Boulassel MR, Toma E, Ahmad A. Decreased levels of circulating IL-21 in HIV-infected AIDS patients: Correlation with CD4+ T-cell counts. Viral Immunol. 21(3), 385-388 (2008).
115. Borg NA, Wun KS, Kjer-Nielsen L et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448(7149), 44-49 (2007).
116. Kim CH, Johnston B, Butcher EC. Trafficking machinery of NKT cells: Shared and differential chemokine receptor expression among V alpha 24+V beta 11+ NKT cell subsets with distinct cytokine-producing capacity. Blood 100(1), 11-16 (2002).
117. Chiba A, Dascher CC, Besra GS, Brenner MB. Rapid NKT cell responses are self-terminating during the course of microbial infection. J. Immunol. 181(4), 2292-2302 (2008).
118. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 195(7), 869-879 (2002).
119. Van Der Vliet HJ, Van Vonderen MG, Molling JW et al. Cutting edge: Rapid recovery of NKT cells upon institution of highly active antiretroviral therapy for HIV-1 infection. J. Immunol. 177(9), 5775-5778 (2006).
120. Van Der Vliet HJJ, Von Blomberg BME, Hazenberg MD et al. Selective decrease in circulating Va24+Vb11+ NKT cells during HIV type 1 infection. J. Immunol. 168(3), 1490-1495 (2002).
121. Montoya CJ, Catano JC, Ramirez Z, Rugeles MT, Wilson SB, Landay AL. Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin. Immunol. 127(1), 1-6 (2008).
122. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog. 4(12), e1000239 (2008).
123. Sada-Ovalle I, Skold M, Tian T, Besra GS, Behar SM. Alpha- galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am. J. Respir. Crit. Care Med. 182(6), 841-847 (2010).
124. Venkataswamy MM, Baena A, Goldberg MF et al. Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus CalmetteYGuerin. J. Immunol. 183(3), 1644-1656 (2009).
125. Kee SJ, Kwon YS, Park YW et al. Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection. Infect. Immun. 80(6), 2100-2108 (2012).
126. Sutherland JS, Jeffries DJ, Donkor S et al. High granulocyte/lymphocyte ratio and paucity of NKT cells defines TB disease in a TB-endemic setting. Tuberculosis 89(6), 398-404 (2009).
127. Garg A, Barnes PF, Porgador A et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J. Immunol. 177(9), 6192-6198 (2006).
128. Vankayalapati R, Wizel B, Weis SE et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J. Immunol. 168(7), 3451-3457 (2002).
129. Parasa VR, Sikhamani R, Raja A. Effect of recombinant cytokines on the expression of natural killer cell receptors from patients with TB or/and HIV infection. PLoS One 7(6), e37448 (2012).
130. Azzoni L, Papasavvas E, Chehimi J et al. Sustained impairment of IFN-g secretion in suppressed HIV-infected patients despite mature NK cell recovery: Evidence for a defective reconstitution of innate immunity. J. Immunol. 168(11), 5764-5770 (2002).
131. Pean P, Nerrienet E, Madec Y et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood 119(14), 3315-3320 (2012).
132. Conradie F, Foulkes AS, Ive P et al. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J. Acquir. Immune Defic. Syndr. 58(3), 309-318 (2011).
133. Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. J. Clin. Virol. 34(4), 233-244 (2005).
134. Brenchley JM, Schacker TW, Ruff LE et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200(6), 749-759 (2004).
135. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434(7037), 1093-1097 (2005).
136. Soghoian DZ, Jessen H, Flanders M et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4(123), 123ra125 (2012).
137. Klatt NR, Silvestri G. CD4+ T cells and HIV: A paradoxical Pas de Deux. Sci. Transl. Med. 4(123), 123ps124 (2012).
138. Pitcher CJ, Quittner C, Peterson DM et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5(5), 518-525 (1999).
139. Toossi Z, Sierra-Madero JG, Blinkhorn RA, Mettler MA, Rich EA. Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type 1. J. Exp. Med. 177(5), 1511-1516 (1993).
140. Toossi Z, Mayanja-Kizza H, Lawn SD, Hirsch CS, Lupo LD, Butera ST. Dynamic variation in the cellular origin of HIV type 1 during treatment of tuberculosis in dually infected subjects. AIDS Res. Hum. Retroviruses 23(1), 93-100 (2007).
141. Hoshino Y, Nakata K, Hoshino S et al. Maximal HIV-1 Replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J. Exp. Med. 195(4), 495-505 (2002).
142. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, Toossi Z. Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J. Infect. Dis. 184(9), 1127-1133 (2001).
143. Canaday DH, Wu M, Lu S et al. Induction of HIV type 1 expression correlates with T cell responsiveness to mycobacteria in patients coinfected with HIV type 1 and Mycobacterium tuberculosis. AIDS Res. Hum. Retroviruses 25(2), 213-216 (2009).
144. Mayanja-Kizza H, Wu M, Aung H et al. The interaction of monocyte chemoattractant protein-1 and tumour necrosis factor-alpha in Mycobacterium tuberculosis-induced HIV-1 replication at sites of active tuberculosis. Scand. J. Immunol. 69(6), 516-520 (2009).
145. Toossi Z, Wu M, Hirsch CS et al. Activation of P-TEFb at sites of dual HIV/TB infection, and inhibition of MTB-induced HIV transcriptional activation by the inhibitor of CDK9, indirubin-3́-monoxime. AIDS Res. Hum. Retroviruses 28(2), 182-187 (2012).
146. Collins KR, Quinones-Mateu ME, Wu M et al. Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J. Virol. 76(4), 1697-1706 (2002).
147. Toossi Z, Mayanja-Kizza H, Baseke J et al. Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis. Clin. Exp. Immunol. 142(2), 327-332 (2005).
148. Thayil SM, Ho YC, Bollinger RC et al. Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIV through a TLR2-mediated pathway. PLoS One 7(7), e41093 (2012).
149. Equils O, Schito ML, Karahashi H et al. Toll-like receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells: Implications of simultaneous activation of TLRs on HIV replication. J. Immunol. 170(10), 5159-5164 (2003).
150. Schutz C, Meintjes G, Almajid F, Wilkinson RJ, Pozniak A. Clinical management of tuberculosis and HIV-1 co-infection. Eur. Respir. J. 36(6), 1460-1481 (2010).
151. Helke KL, Mankowski JL, Manabe YC. Animal models of cavitation in pulmonary tuberculosis. Tuberculosis (Edinb.) 86(5), 337-348 (2006).
152. Chen CY, Huang D, Wang RC et al. A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog. 5(4), e1000392 (2009).
153. Price NM, Farrar J, Tran TT, Nguyen TH, Tran TH, Friedland JS. Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo. J. Immunol. 166(6), 4223-4230 (2001).
154. Elkington PT, Nuttall RK, Boyle JJ et al. Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am. J. Respir. Crit. Care Med. 172(12), 1596-1604 (2005).
155. Elkington P, Shiomi T, Breen R et al. MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J. Clin. Invest. 121(5), 1827-1833 (2011).
156. Elkington PT, D'Armiento JM, Friedland JS. Tuberculosis immunopathology: The neglected role of extracellular matrix destruction. Sci. Transl. Med. 3(71), 71ps76 (2011).
157. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int. J. Tuberc. Lung Dis. 6(8), 713-719 (2002).
158. Walker NF, Clark SO, Oni T et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 185(9), 989-997 (2012).
159. Liuzzi GM, Mastroianni CM, Santacroce MP et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J. Neurovirol. 6(2), 156-163 (2000).
160. Dhawan S, Toro LA, Jones BE, Meltzer MS. Interactions between HIV-infected monocytes and the extracellular matrix: HIV-infected monocytes secrete neutral metalloproteases that degrade basement membrane protein matrices. J. Leukoc. Biol. 52(2), 244-248 (1992).
161. Mastroianni CM, Liuzzi GM. Matrix metalloproteinase dysregulation in HIV infection: Implications for therapeutic strategies. Trends Mol. Med. 13(11), 449-459 (2007).
162. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61(3), 259-266 (2006).
163. Elkington PT, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 142(1), 12-20 (2005).
164. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111(5), 635-646 (2002).
165. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289(5482), 1202-1206 (2000).
166. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100(4), 1160-1167 (2002).
167. Harris JE, Fernandez-Vilaseca M, Elkington PT, Horncastle DE, Graeber MB, Friedland JS. IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J. 21(2), 356-365 (2007).
168. Toossi Z, Hirsch CS, Wu M, Mayanja-Kizza H, Baseke J, Thiel B. Distinct cytokine and regulatory T cell profile at pleural sites of dual HIV/tuberculosis infection compared to that in the systemic circulation. Clin. Exp. Immunol. 163(3), 333-338 (2011).
169. Boehme CC, Nicol MP, Nabeta P et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 377(9776), 1495-1505 (2011).
170. Cox JA, Lukande RL, Nelson AM et al. An autopsy study describing causes of death and comparing clinicoYpathological findings among hospitalized patients
171. Graham NM, Nelson KE, Solomon L et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 267(3), 369-373 (1992).
172. Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy. JAMA 268(4), 504-509 (1992).
173. Lalvani A. Diagnosing tuberculosis infection in the 21st century: New tools to tackle an old enemy. Chest 131(6), 1898-1906 (2007).
174. Oni T, Wilkinson RJ. Immunodiagnosis of tuberculosis in HIV-infected adults in settings of high HIV/tuberculosis burden. Eur. Respir. Dis. 8(2), 148-153 (2012).
175. Santin M, Munoz L, Rigau D. Interferon-gamma release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: A systematic review and meta-analysis. PLoS One 7(3), e32482 (2012).
176. Rangaka MX, Wilkinson KA, Glynn JR et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: A systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 45-55 (2012).
177. Machingaidze S, Verver S, Mulenga H et al. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am. J. Respir. Crit. Care Med. doi:10.1164/rccm.201206-1134OC (2012) (Epub ahead of print).
178. Mitchell JE, Chetty S, Govender P et al. Prospective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individuals. PLoS One 7(6), e37920 (2012).
179. Evans TG, Bonnez W, Soucier HR, Fitzgerald T, Gibbons DC, Reichman RC. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res. 39(3), 163-173 (1998).
180. Mezzaroma I, Carlesimo M, Pinter E et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 13(10), 1187-1193 (1999).
181. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277(5322), 112-116 (1997).
182. Havlir DV, Kendall MA, Ive P et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365(16), 1482-1491 (2011).
183. Blanc F-X, Sok T, Laureillard D et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 365(16), 1471-1481 (2011).
184. Abdool Karim SS, Naidoo K, Grobler A et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 362(8), 697-706 (2010).
185. Wendland T, Furrer H, Vernazza PL et al. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 13(14), 1857-1862 (1999).
186. Sutherland R, Yang H, Scriba TJ et al. Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS 20(6), 821-829 (2006).
187. Schluger NW, Perez D, Liu YM. Reconstitution of immune responses to tuberculosis in patients with HIV infection who receive antiretroviral therapy. Chest 122(2), 597-602 (2002).
188. Mendonca M, Tanji MM, Silva LC et al. Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease. Clin. Immunol. 125(1), 60-66 (2007).
189. Burdo TH, Lentz MR, Autissier P et al. Soluble CD163 made by monocyte/ macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. Infect. Dis. 204(1), 154-163 (2011).
190. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: Implication for HIV eradication. Antiviral Chem. Chemother. 20(2), 63-78 (2009).
191. Hadad N, Levy R, Schlaeffer F, Riesenberg K. Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition. Clin. Vaccine Immunol. 14(11), 1515-1521 (2007).
192. Cobos-Jimenez V, Booiman T, Hamann J, Kootstra NA. Macrophages and HIV-1. Curr. Opin. HIV AIDS 6(5), 385-390 (2011).
193. Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: Case definitions for use in resource-limited settings. Lancet Infect. Dis. 8(8), 516-523 (2008).
194. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and meta-analysis. Lancet Infect. Dis. 10(4), 251-261 (2010).
195. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect. Dis. 5(6), 361-373 (2005).
196. Pepper DJ, Marais S, Maartens G et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: A case series. Clin. Infect. Dis. 48(11), e96-e107 (2009).
197. Salliot C, Guichard I, Daugas E, Lagrange M, Verine J, Molina JM. Acute kidney disease due to immune reconstitution inflammatory syndrome in an HIV-infected patient with tuberculosis. J. Int. Assoc. Physicians AIDS Care (Chic.) 7(4), 178-181 (2008).
198. Breton G, Duval X, Estellat C et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin. Infect. Dis. 39(11), 1709-1712 (2004).
199. Wang SH, Menon A, Hyslop NE. Cardiac tamponade: An unusual complication of simultaneous treatment of tuberculosis and HIV. South. Med. J. 101(5), 558-560 (2008).
200. Marais S, Meintjes G, Pepper DJ et al. Frequency, severity and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin. Infect. Dis. (2012) (In press).
201. Burman W, Weis S, Vernon A et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int. J. Tuberc. Lung Dis. 11(12), 1282-1289 (2007).
202. Meintjes G, Wilkinson RJ, Morroni C et al Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 24(15), 2381-2390 (2010).
203. Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Curr. HIV/AIDS Rep. 9(3), 238-250 (2012).
204. Naidoo K, Yende-Zuma N, Padayatchi N et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: Findings from the SAPiT trial. Ann. Intern. Med. 157(5), 313-324 (2012).
205. Smith CJ, Sabin CA, Lampe FC et al. The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy. AIDS 17(7), 963-969 (2003).
206. Bourgarit A, Carcelain G, Martinez V et al. Explosion of tuberculin-specific Th1- responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20(2), F1-F7 (2006).
207. Tan DB, Yong YK, Tan HY et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med. 9(5), 307-316 (2008).
208. Bourgarit A, Carcelain G, Samri A et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J. Immunol. 183(6), 3915-3923 (2009).
209. Meintjes G, Wilkinson KA, Rangaka MX et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 178(10), 1083-1089 (2008).
210. Tieu HV, Ananworanich J, Avihingsanon A et al. Immunologic markers as predictors of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV and tuberculosis coinfected persons in Thailand. AIDS Res. Hum. Retroviruses 25(11), 1083-1089 (2009).
211. Elliott JH, Vohith K, Saramony S et al. Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J. Infect. Dis. 200(11), 1736-1745 (2009).
212. Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune reconstitution disease with bronchiolitis obliterans organizing pneumonia: The role of macrophages. AIDS 23(1), 143-145 (2009).
213. Tan DB, Lim A, Yong YK et al. TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease. AIDS 25(12), 1455-1460 (2011).
214. Ruhwald M, Ravn P Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS 21(7), 882-884 (2007).
215. Tadokera R, Meintjes G, Skolimowska KH et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Respir. J. 37(5), 1248-1259 (2010).
216. Meintjes G, Skolimowska KH, Wilkinson KA et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 186(4), 369-377 (2012).
217. Oliver BG, Elliott JH, Price P et al. Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy. J. Infect. Dis. 202(11), 1728-1737 (2010).
218. Oliver BG, Elliott JH, Price P, Phillips M, Cooper DA, French MA. Tuberculosis after commencing antiretroviral therapy for HIV infection is associated with elevated CXCL9 and CXCL10 responses to Mycobacterium tuberculosis antigens. J. Acquir. Immune Defic. Syndr. 61(3), 287-292 (2012).
219. Barber DL, Mayer-Barber KD, Antonelli LR et al. Th1-driven immune reconstitution disease in Mycobacterium avium-infected mice. Blood 116(18), 3485-3493 (2010).
220. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: The trouble with immunity when you had none. Nat. Rev. Microbiol. 10(2), 150-156 (2012).
221. Zaidi I, Peterson K, Jeffries D et al. Immune reconstitution inflammatory syndrome and the influence of T regulatory cells: A cohort study in The Gambia. PLoS One 7(6), e39213 (2012).
222. Seddiki N, Sasson SC, Santner-Nanan B et al. Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur. J. Immunol. 39(2), 391-403 (2009).
223. Lim A, D'Orsogna L, Price P, French MA. Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. AIDS Res. Ther. 5, 9 (2008).
224. Bourgarit A, Carcelain G, Samri A et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative gammadelta T cells. J. Immunol. 183(6), 3915-3923 (2009).
225. Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev. Vaccines 10(5), 645-658 (2011).
226. WHO. Global Advisory Committee on Vaccine Safety, 3-4 December 2009. Use of BCG vaccine in HIV-infected infants. Weekly Epidemiol. Rec. 85, 29-36 (2010).
227. Schoeman JF, Fieggen G, Seller N, Mendelson M, Hartzenberg B. Intractable intracranial tuberculous infection responsive to thalidomide: Report of four cases. J. Child Neurol. 21(4), 301-308 (2006).
228. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr. HIV/AIDS Rep. 6(3), 162-171 (2009).
229. Thwaites GE, Nguyen DB, Nguyen HD et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351(17), 1741-1751 (2004).
230. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 84(2), 183-188 (2000).